Medindia

X

Rivastigmine Tartrate Capsules Recalled from the US Market by Dr Reddy’s Laboratories

by Lakshmi Darshini on  August 21, 2015 at 7:04 PM Drug News   - G J E 4
A voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the US market has been initiated by Dr Reddy's Laboratories (DRL), following 'Failed Dissolution Specifications'.
Rivastigmine Tartrate Capsules Recalled from the US Market by Dr Reddy’s Laboratories
Rivastigmine Tartrate Capsules Recalled from the US Market by Dr Reddy’s Laboratories
Advertisement

A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA). According to a notification issued by the agency, the batch was manufactured at DRL's Ltd, Bachupally unit and the recall was initiated under "Class II" classification. Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease.

Advertisement
According to the US health regulator, Class II recall is a situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All